4-OH tamoxifen does not interfere with bicalutamide inhibitory effects on human prostatic cancer cells In vitro

Anticancer Research

Volumn 25, Issue 6 B, 2005, Pages 4277-4280

  Boccardo, F ^a,b   Medicina, D ^a,c   Galmozzi, F ^a   Emionite, L ^a   Lo Casto, M ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c City Hospital   (Italy)

Author keywords

4 OH tamoxifen; Bicalutamide; LNCaP cells

Indexed keywords

4 HYDROXYTAMOXIFEN; ANDROSTANOLONE; BICALUTAMIDE; COLLAGEN; CRYSTAL VIOLET; TRYPSIN;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CROSS REACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; INHIBITION KINETICS; MALE; PRIORITY JOURNAL; PROSTATE CANCER; STAINING; THREE DIMENSIONAL IMAGING;

ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; TAMOXIFEN;

EID: 27944472574     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Iversen P, Tyrrell CJ, Kaisary AV et al: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up, J Urol 164: 1579-1582, 2000.
2. Boccardo F, Rubagotti A, Barichello M et al: Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol 17: 2027-2038, 1999.
3. Boccardo F: Hormone therapy of prostate cancer: is there a role for antiandrogen monotherapy? Crit Rev Oncol Hematol 35(2): 121-132, 2000.
4. See WA, McLeod D, Iversen P et al: The bicalutamide Early Prostate Cancer Program: Demography. Urol Oncol 6: 43-47, 2001.
5. See WA, Wirth M, McLeod DG et al: Bicalutamide as immediate therapy, either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: First analysis of the Early Prostate Cancer Program. J Urol 168: 429-435, 2002.
6. Smith MR, Goode M, Zietman AL et al: Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol 1: 2546-2553, 2004.
7. Boccardo F, Rubagotti A, Battaglia M et al: Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 23(4): 808-815, 2005.
8. Saltzstein D, Cantwell A, Sieber P et al: Prophylactic tamoxifen significantly reduces the incidence of bicalutamide-induced gynecomastia and breast pain. Br J Urol 90: 120-1, 2002 (abstr PD-4.07).
9. Boccardo F, Conti G, Potenzoni D et al: Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer. Cancer Chemother Pharmacol 19, 2005.
10. Horoszewicz JS, Leong SS, Kawinski E et al: LNCaP model of human prostatic carcinoma. Cancer Res 43(4): 1809-1818, 1983.
11. Schuurmans AL, Bolt J and Mulder E: Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP. Prostate 12(1): 55-63, 1988.
12. Rossi L, Boccardo F and Corvo R: Endothelial cells increase the radiosensitivity of oropharyngeal squamous carcinoma cells in collagen gel. Oral Oncol 40(2): 214-222, 2004.
13. Cukierman E, Pankov R and Yamada KM: Cell interactions with three-dimensional matrices. Curr Opin Cell Biol 14(5): 633-639, 2002.
14. Schuurmans AL, Bolt J and Veldscholte J: Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion. J Steroid Biochem Mol Biol 37(6): 849-853, 1990.
15. Wilding G, Chen M and Gelmann EP: Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 14(2): 103-115, 1989.
16. Castagnetta LA, Miceli MD and Sorci CMI: Growth of LNCaP human prostate cancer cells is stimulated by estradiol via its own receptor. Endocrinology 136(5): 2309-2319, 1995.
17. Furr BJ: The development of Casodex (bicalutamide): preclinical studies. Eur Urol 29(Suppl 2): 83-95, 1996.